The "microscopic" revolution in breast carcinoma: Are we ready to change clinical practice?

Cancer

Volumn 103, Issue 5, 2005, Pages 877-880

  Cristofanilli, Massimo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETASTATIC AGENT; CYTOKERATIN;

BLOOD; BONE MARROW BIOPSY; BONE MARROW DISEASE; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; FOLLOW UP; HUMAN; IMAGING AND DISPLAY; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MICROSCOPY; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

BIOPSY; BONE MARROW; BREAST NEOPLASMS; CARCINOMA; FEMALE; FOLLOW-UP STUDIES; HUMANS; KERATINS; NEOPLASM CIRCULATING CELLS; NEOPLASM METASTASIS; NEOPLASM, RESIDUAL; PHYSICIAN'S PRACTICE PATTERNS; TIME FACTORS;

EID: 13944252095     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20838     Document Type: Review

References (20)

1. Maslak P. Clinical applications of molecular monitoring in leukemia. Curr Hematol Rep. 2003;2:43-48.
2. Szczepanski T, Orfao A, van der Velden VH, San Miguel JF, van Dongen JJ. Minimal residual disease in leukaemia patients. Lancet Oncol. 2001;2:409-417.
3. Clare SE, Sener SF, Wilkens W, Goldschmidt R, Merkel D, Winchester DJ. Prognostic significance of occult lymph node metastases in node negative breast cancer. Ann Surg Oncol. 1997;4:447-451.
4. Braun S, Pantel K, Müller P, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with Stage I, II or III breast cancer. N Engl J Med. 2000;342:525-533.
5. Cristofanilli M, Budd GT, Ellis M, et al. Circulating tumor cells predict progression free survival and overall survival in metastatic breast cancer. N Engl J Med. 2004;351:781-791.
6. Reed W, Bohler PJ, Sandstad B, Nesland JM. Occult metastases in axillary lymph nodes as a predictor of survival in node-negative breast carcinoma with long-term follow-up. Breast J. 2004;10:174-180.
7. Singletary SE, Allred C, Ashley P, et al. Staging system for breast cancer: revisions for the 6th edition of the AJCC cancer staging manual. Surg Clin North Am. 2003;83:803-819.
8. Wiedswang G, Borgen E, Karesen R, et al. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol. 2003;21: 3469-3478.
9. Janni W, Rack B, Schindlbeck C, et al. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer. 2005;103:884-891.
10. Wiedswang G, Borgen E, Karesen R, et al. Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome. Clin Cancer Res. 2004;10:5342-5348.
11. Hansen NM, Ye X, Grube BJ, Giuliano AE. Manipulation of the primary breast tumor and the incidence of sentinel node metastases from invasive breast cancer. Arch Surg. 2004;139: 634-639; discussion, 639-640.
12. Braun S, Kentenich C, Janni W, et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol. 2000;18:80-86.
13. Banerjee M, George J, Song EY, Roy A, Hryniuk W. Tree-based model for breast cancer prognostication, J Clin Oncol. 2004;22:2567-2575.
14. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology. 2004;231:305-332.
15. Terstappen LW, Rao C, Gross S, Weiss AJ. Peripheral blood tumor cell load reflects the clinical activity of the disease in patients with carcinoma of the breast. Int J Oncol. 2000;17: 573-578.
16. Pantel K, Schlimok G, Braun S, et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst. 1993;85:1419-1424.
17. Fehm T, Sagalowsky A, Clifford E, et al. Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res. 2002;8:2073-2084.
18. Warmuth M, Damoiseaux R, Liu Y, Fabbro D, Gray N. SRC family kinases: potential targets for the treatment of human cancer and leukemia. Curr Pharm Des. 2003;9:2043-2059.
19. Fernandis AZ, Prasad A, Band H, Klosel R, Ganju RK. Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells. Oncogene. 2004;23:157-167.
20. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410: 50-56.